262 related articles for article (PubMed ID: 12731043)
1. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
[TBL] [Abstract][Full Text] [Related]
2. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
3. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
[TBL] [Abstract][Full Text] [Related]
4. New strategies of mammary cancer vaccination.
Accolla RS; Frangione V; De Lerma Barbaro A; Mortara L
Breast J; 2010; 16 Suppl 1():S42-4. PubMed ID: 21050309
[TBL] [Abstract][Full Text] [Related]
5. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.
Rosato A; Dalla Santa S; Zoso A; Giacomelli S; Milan G; Macino B; Tosello V; Dellabona P; Lollini PL; De Giovanni C; Zanovello P
Cancer Res; 2003 May; 63(9):2158-63. PubMed ID: 12727834
[TBL] [Abstract][Full Text] [Related]
6. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
7. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
[TBL] [Abstract][Full Text] [Related]
8. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
9. Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
Frey AB
J Immunol; 1995 May; 154(9):4613-22. PubMed ID: 7722313
[TBL] [Abstract][Full Text] [Related]
10. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection.
Felix NJ; de Serres S; Meyer AA; Ting JP
J Surg Res; 2002 Feb; 102(2):185-92. PubMed ID: 11796017
[TBL] [Abstract][Full Text] [Related]
12. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.
Martin BK; Frelinger JG; Ting JP
J Immunol; 1999 Jun; 162(11):6663-70. PubMed ID: 10352284
[TBL] [Abstract][Full Text] [Related]
13. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.
Arancibia-Cárcamo CV; Osawa H; Arnett HA; Háskova Z; George AJ; Ono SJ; Ting JP; Streilein JW
Eur J Immunol; 2004 Feb; 34(2):471-80. PubMed ID: 14768052
[TBL] [Abstract][Full Text] [Related]
14. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
15. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP
J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977
[TBL] [Abstract][Full Text] [Related]
16. Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer.
Mortara L; Giuliani L; De Lerma Barbaro A; Accolla RS; Noonan DM
Surg Oncol; 2007 Dec; 16 Suppl 1():S33-6. PubMed ID: 18035537
[TBL] [Abstract][Full Text] [Related]
17. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
Townsend SE; Su FW; Atherton JM; Allison JP
Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
[TBL] [Abstract][Full Text] [Related]
18. Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity.
Leach DR; Callahan GN
J Immunol; 1995 Jan; 154(2):738-43. PubMed ID: 7814880
[TBL] [Abstract][Full Text] [Related]
19. Rejection of mouse sarcoma cells after transfection of MHC class II genes.
Ostrand-Rosenberg S; Thakur A; Clements V
J Immunol; 1990 May; 144(10):4068-71. PubMed ID: 2332639
[TBL] [Abstract][Full Text] [Related]
20. Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA.
Bradley MB; Fernandez JM; Ungers G; Diaz-Barrientos T; Steimle V; Mach B; O'Reilly R; Lee JS
J Immunol; 1997 Aug; 159(3):1086-95. PubMed ID: 9233601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
